NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company based in Wilmington, United States, has recently filed definitive proxy materials for its 2026 annual meeting, scheduled for December 17. The company, which specializes in the research and development of investigational medicines, is actively engaged in creating treatments for Covid-19, other respiratory conditions, suicidal depression, and PTSD. NRX Pharmaceuticals trades on the Nasdaq stock exchange and has a market capitalization of $98,210,000 USD as of November 5, 2026.
The proxy materials outline several key proposals for the upcoming annual meeting. Notably, the board has nominated Dennis McBride for a Class II director seat. Additionally, the company plans to seek shareholder ratification for Weinberg & Company to serve as its independent auditors for the fiscal year ending December 31, 2026.
In an effort to reduce costs and minimize environmental impact, NRX Pharmaceuticals has opted for a virtual-only format for the annual meeting. This approach ensures that all stockholders retain full voting rights while participating in the meeting remotely. Proxy materials are available to shareholders both electronically and by mail, facilitating easy access to the necessary information for voting.
The company has committed to covering all expenses related to the solicitation of proxies and the hosting of the virtual meeting. Shareholders are encouraged to review the proxy statement for detailed guidance on how to access and submit their votes.
NRX Pharmaceuticals, Inc. was initially public through an Initial Public Offering (IPO) in November 2017. For further information on the company’s activities and developments, stakeholders can visit their website at www.nrxpharma.com .
As of the close of trading on November 5, 2026, the company’s stock price stood at $2.38 USD. The stock has experienced a 52-week high of $5.055 on June 1, 2026, and a 52-week low of $1.62 on March 8, 2026. The company’s price-to-earnings ratio is currently listed as -3, reflecting its status as a clinical-stage entity with ongoing research and development activities.
